Gastroparesis in ME/CFS: A Real, Measurable Slow Stomach — and a Safe Way to Manage It
You eat a small meal and you are full for hours. You feel nauseous. Your abdomen bloats. Sometimes you vomit food that you can still see. Over time, you start to fear eating. You start to eat only liquids. You stop eating with other people.
This article asks a direct question: is the slow stomach a real, measurable feature of ME/CFS — or is it just how you feel?
The short answer: it is real, and it is measurable. A controlled study measured how fast the stomach empties in 32 people with chronic fatigue syndrome and found that most of them emptied slowly; the delay tracked with how sick they felt (Burnet and Chatterton 2004). This is not a vague complaint. It is a finding you can test with a standard scan.
This article separates what we know from what our research adds. What we know: delayed gastric emptying is documented in a ME/CFS cohort, and gastroparesis is a well-characterised problem in diabetes and, increasingly, in the post-viral setting. What our research adds: the specific reading that ME/CFS gastroparesis is a measurable autonomic manifestation with a safe, ordered treatment ladder — and that its mechanism is genuinely unresolved, with three candidate explanations and none confirmed in ME/CFS.
For the broader picture of how GI dysmotility and SIBO fit together in ME/CFS — the mast-cell axis, the hydrogen-sulfide mechanism, and the full treatment menu — see GI Dysmotility Article 1 and the companion treatment article. This article does not repeat that content. It goes deeper on the emptying measurement, the mechanism uncertainty, and the safety-managed treatment ladder.
1 The measurable finding
The anchor is a controlled radionuclide study. It measured gastric emptying — the time it takes the stomach to clear a meal — in 32 people with chronic fatigue syndrome, using a standardised scan that tracks a small amount of radioactive marker in both a liquid and a solid meal (Burnet and Chatterton 2004).
The result: 23 of 32 (72%) had delayed liquid emptying, and 12 of 32 (38%) had delayed solid emptying. The delay correlated significantly with the mean symptom score (p < 0.001) — the sicker the patient, the slower the stomach.
This is direct ME/CFS evidence that delayed gastric emptying is a real, measurable feature of the illness, not merely a subjective complaint. It can be assessed with a standard gastric emptying test, and it may be a target for treatment rather than something a patient must simply endure.
The honest caveat. The finding rests on a single 2004 cohort of 32 people. The study predates the modern diagnostic criteria for ME/CFS (the 2015 IOM and 2011 ICC criteria), and the finding has not been replicated in a modern-criteria cohort. In our evidence register this is a clinical finding with a certainty of 0.60 — solid, but anchored on one old study. The study did not report the severity of its participants, so we do not know whether the delay is stronger in severe or very-severe patients.
One counterpoint: a single adolescent case report found normal gastric emptying and normal myoelectrical activity in a young person with CFS (Corrado et al. 1998). Delayed emptying is therefore not universal in the illness. The case is one person, pediatric, and carries low evidentiary weight — it does not overturn the larger cohort finding, but it shows the delay is not present in every case.
2 What it feels like: the anxiety of a stomach you cannot trust
The numbers above are a scan. The experience is different.
When the stomach empties slowly, eating stops being a neutral act. It becomes a risk. You eat, and within minutes you feel full, bloated, or nauseous. You learn to fear the meal. You learn to fear the moment you might vomit in front of other people. You stop eating with others, because you cannot predict what will happen. You start to weigh every bite.
Over time, people tend to change their eating in the same direction. They eat smaller amounts, more often. They cut out the foods that sit heaviest — the fatty ones, the high-fibre ones. And many go to liquids: smoothies, broths, nutritional drinks, soups. Liquids empty faster than solids, so they feel safer. Eating only liquids is not a whim. It is a rational adaptation to a stomach that genuinely clears solids slowly.
This matters for two reasons. First, the anxiety is real and it has a cost. Fear of eating can narrow the diet to the point of malnutrition and weight loss, and it can tip into a disordered relationship with food that needs its own support — not just a diet sheet. A patient who is afraid to eat is a patient who needs a clinician, not more willpower.
Second, the adaptation is not wrong. The shift to small, frequent, low-fat, low-fibre meals and to liquid or semi-liquid nutrition is exactly the first-line, lowest-risk strategy that the evidence supports (see the treatment section below). The patient’s instinct and the evidence point the same way. The gap is that the patient usually arrives at it alone, by trial and error, without the safety net of a clinician watching weight and nutrition.
3 What the stomach is doing
The clinical picture of gastroparesis in ME/CFS is a recognisable set of symptoms:
- Feeling full after small amounts of food
- Persistent nausea
- Vomiting, especially of undigested food
- Abdominal bloating and discomfort
- Unpredictable blood sugar fluctuations
The mechanism is thought to be autonomic. The vagus nerve controls the motility of the stomach — the waves of contraction that grind food and push it onward. The leading reading is that autonomic dysfunction reduces vagal drive to the stomach in ME/CFS, so it empties slowly; that reading is a hypothesis, not yet proven in ME/CFS. Whatever the cause, the impaired emptying produces the digestive symptoms and the nutritional challenges above.
This is the functional reading: the stomach’s motor program is under-driven by the autonomic nervous system. It is the simplest explanation, and it fits the autonomic dysfunction that ME/CFS is known for. But it is not the only explanation, and it is not the one the evidence has settled on. We return to the alternatives after looking at the limits of the evidence.
There is a second consequence that matters specifically in ME/CFS. Erratic emptying is likely to mean erratic absorption — glucose and nutrients reach the blood in unpredictable bursts rather than a steady stream, because the rate at which the stomach empties shapes the postprandial glucose response (Camilleri 2026). This is a reasonable inference from the physiology, not yet demonstrated in an ME/CFS cohort. For a person already managing a tight energy envelope and orthostatic intolerance, that instability would add a metabolic load on top of the gastric discomfort. It is one more reason the slow stomach is not just a local nuisance but part of the wider energy picture.
4 The honest limits
Before the mechanism question, the limits. The evidence that ME/CFS patients have delayed gastric emptying is real but thin, and it has specific weaknesses:
- One old cohort. The direct evidence rests largely on the single 2004 cohort of 32 people, which predates modern diagnostic criteria (Burnet and Chatterton 2004).
- One null case. The one direct counter-example is a single adolescent with normal emptying (Corrado et al. 1998).
- No modern replication. No cohort using the current IOM/ICC criteria has replicated the finding.
- Non-specific alternatives. Several explanations other than a distinct ME/CFS gastroparesis lesion can produce the same symptom pattern: medication side-effects (many drugs used in ME/CFS slow gastric emptying), functional dyspepsia with abnormal stomach accommodation and visceral hypersensitivity rather than true emptying delay (Debourdeau et al. 2024), deconditioning or the general effects of severe illness, and subjective reporting bias that inflates symptom-based prevalence.
- Discounted cross-disease support. The mechanistic support from diabetic and idiopathic gastroparesis histology (Grover et al. 2011) and animal models (Wang et al. 2009) comes from other populations and does not by itself establish that ME/CFS shares that pathology.
The practical consequence: before acting on a gastroparesis diagnosis in ME/CFS, a clinician should recognise the evidence is a single old cohort and should exclude the common non-specific causes — drug effects, dyspepsia — with objective testing, rather than assuming a distinct ME/CFS-specific emptying defect. This is a risk assessment, not a positive claim, and the caution applies across all severities.
5 The mechanism question: three candidates, none confirmed
This is the genuinely open part of the story. We do not yet know what is structurally or functionally wrong with the stomach in ME/CFS. Three candidates are on the table, and they point to different treatments.
Candidate 1 — structural loss of the stomach’s pacemaker cells and enteric nerves. In diabetic and idiopathic gastroparesis, human gastric tissue shows a loss of the interstitial cells of Cajal (the pacemaker cells of the stomach), a reduction in enteric nerve fibres, and altered resident macrophages (Grover et al. 2011). An animal model of diabetic gastroparesis confirms that loss of these cells and nerves is accompanied by slowed emptying (Wang et al. 2009). Whether ME/CFS shares this structural degeneration is unknown — no ME/CFS gastric histology has been published. In our register, the extrapolation of this finding to ME/CFS is an open question with a certainty of 0.40. If it is true, then prokinetic drugs that stimulate surviving nerves have a built-in limit, and treatment would need to target the prevention or replacement of the cell loss instead.
Candidate 2 — autoimmune blockade of the ganglionic acetylcholine receptor. A case of autoimmune gastrointestinal dysmotility after SARS-CoV-2 infection presented with intractable nausea, early satiety, delayed gastric emptying, and antibodies against the ganglionic acetylcholine receptor — and it improved substantially with immunotherapy (Montalvo et al. 2022). By analogy, a subset of ME/CFS patients with gastroparesis could have an autoimmune ganglionic (vagal/enteric) blockade rather than structural nerve loss — a mechanism that would be potentially reversible with immunotherapy rather than irreversible. This is a speculation for ME/CFS with a certainty of 0.30: no ME/CFS cohort has been screened for these antibodies, and the only directly analogous evidence is a single post-viral (Long COVID) case report.
Candidate 3 — functional vagal failure alone. The stomach’s motor program is under-driven by the autonomic nervous system, with no structural cell loss and no autoantibody. This is the simplest reading and the one the clinical picture fits, but it is a diagnosis of exclusion: it holds only if candidates 1 and 2 are ruled out. In our register it is a clinical reading rather than an independently evidenced finding, so we give it no separate certainty value.
These three are not mutually exclusive, and the distinction matters clinically. A structural loss limits what a prokinetic can do. An autoimmune blockade is potentially reversible. A functional failure is the one most likely to respond to prokinetic drugs. The honest position is that we do not yet know which one — or which combination — applies to a given patient, and no test currently separates them in ME/CFS.
Each candidate has a falsifiable prediction. A gastric antral biopsy from ME/CFS patients with documented gastroparesis showing normal pacemaker-cell and enteric-nerve density would falsify the structural-loss reading; evidence of cell or nerve loss would support it. Measuring ganglionic acetylcholine-receptor antibodies in a ME/CFS gastroparesis cohort — if a meaningful subset is antibody-positive and their emptying improves after immunotherapy, the autoimmune-blockade claim is supported; if antibody levels do not track emptying delay or immunotherapy response, it is falsified. Candidate 3 is testable too: if emptying delay tracks non-invasive vagal-tone markers (such as heart-rate-variability indices) and improves with autonomic therapies that raise vagal drive, the functional-failure reading is supported; if emptying stays slow while those markers normalise, it is weakened. The emptying delay itself — the shared feature behind all three — can be measured with a standard gastric emptying scan; telling the candidates apart would need the biopsy and antibody testing above, alongside non-invasive autonomic measures, and none of that has been done in an ME/CFS cohort.
6 A cross-disease mirror
Gastroparesis is not unique to ME/CFS. It is well-characterised in other settings, and the parallels are informative:
- Diabetes. Gastroparesis is a well-characterised complication of diabetes mellitus, where the structural loss of pacemaker cells and enteric nerves is documented in human tissue (Grover et al. 2011) and in animal models (Wang et al. 2009).
- Post-viral (Long COVID). Autoimmune gastrointestinal dysmotility has been reported after SARS-CoV-2 infection, presenting with intractable nausea, early satiety, delayed gastric emptying, and antibodies against ganglionic acetylcholine receptors, with improvement after immunotherapy (Montalvo et al. 2022).
- POTS and hypermobility. In the autonomic/hypermobility overlap — POTS and hypermobile Ehlers–Danlos syndrome — GI dysmotility and gastroparesis are common and can require non-oral nutritional support in severe cases Aziz et al. (2025).
These parallels support gastroparesis as a plausible manifestation of the autonomic and autoimmune dysfunction implicated in ME/CFS, and as a source of nutritional risk in severe illness. They also give clinicians a management playbook — the POTS/hypermobility framework is the most transferable — while the cross-population gap is flagged: what is established in those populations is not yet proven in ME/CFS.
7 What to do about it: a safe, ordered pathway
The treatment story has two rungs, and the order matters. The lowest-risk step comes first.
First-line: dietary and nutritional management. For moderate-to-severe gastroparesis, dietary modification and feeding strategy are the first-line, lowest-risk interventions: small frequent meals, low-fat and low-fibre meals to reduce the mechanical load on the stomach, and liquid or semi-liquid nutrient options when solid emptying is slow (Gupta and Lee 2016). Not all liquids are equal: thin broths and soups are low in calories, so a shift to liquids needs guidance on energy and protein targets, not just a switch of texture. In the autonomic/POTS population, GI dysmotility with feeding intolerance is a recognised driver of the need for non-oral (enteral or parenteral) nutritional support in the most affected patients (Tseng et al. 2019). These measures do not reverse the underlying autonomic dysfunction, but they are essential to maintain nutrition and prevent avoidable weight loss in severe and very-severe ME/CFS. They apply across severity; the enteral escalation is a very-severe, feeding-failure measure. This first-line rung is also where a medication review belongs — including, where relevant, a GLP-1 receptor agonist (see below).
This is the rung the patient’s own instinct usually reaches first — the shift to small, frequent, liquid meals described above. The evidence confirms the instinct and adds the safety net: a clinician watching weight, nutrition, and the point at which oral feeding is no longer enough.
Second-line: prokinetics, safety-managed. Prokinetic drugs are the main pharmacological option for gastroparesis and are evidence-based in the general gastroparesis population (Ingrosso et al. 2023). They carry serious risks that are especially relevant to severe and very-severe ME/CFS patients, and none is validated in ME/CFS; nor is any herbal or over-the-counter “motility” supplement, which can interact with cardiac and other medications — do not self-prescribe supplements for this. The prescription drugs considered are:
- Metoclopramide is the only FDA-approved drug for gastroparesis, but it carries a black-box warning for use beyond 12 weeks because of tardive dyskinesia, which may be irreversible; it also causes drowsiness, restlessness, and hyperprolactinaemia (Shakhatreh et al. 2019). In pregnancy it has reassuring first-trimester data on major congenital malformations (Sun et al. 2021), but it still needs specialist review in pregnancy or lactation.
- Domperidone can prolong the cardiac QT interval — a baseline ECG/QT assessment and QTc monitoring are prudent before and during use (Ingrosso et al. 2023); in Europe it is restricted to short-term use on these cardiac grounds (EMA, 2014) (Yüksel and Tuǧlular 2019).
- Erythromycin (as a motilin agonist) loses effectiveness with prolonged use through receptor desensitisation (Ingrosso et al. 2023).
- Highly selective 5-HT4 agonists (for example prucalopride) show efficacy with no excess pooled cardiovascular/QT signal in trials (Patel et al. 2024), but they are not approved for gastroparesis in all jurisdictions.
One class to check, not a prokinetic option: GLP-1 receptor agonists are contraindicated in established gastroparesis. They slow gastric emptying (Nauck et al. 2011) and are a recognised cause of medication-induced gastroparesis (Camilleri and Jencks 2025); they also suppress appetite and can worsen weight loss and nausea — all of which are already problematic in severe ME/CFS. If a patient on a GLP-1 has slow emptying, it is worth asking the prescriber whether the delay began after the drug started; if it clearly did, a clinician may consider a supervised trial hold or discontinuation, which in some cases resolves the picture before any prokinetic is considered. That is a clinical judgement, not established guidance, and the timing question is for the prescriber, not something to decide alone. Do not stop a prescribed GLP-1 on your own. Their use in a patient with gastroparesis requires explicit review against this risk.
Two hard limits apply. First, no prokinetic has been tested in a controlled ME/CFS trial, so dosing and safety must be extrapolated from other populations. Second, prokinetics do not treat the underlying autonomic dysfunction; they are best combined with the dietary measures above. For a severe or very-severe patient, the cautious approach is an evidence-based trial with the lowest-risk agent, close monitoring for extrapyramidal, cardiac, and autonomic effects, and explicit time-limited use. A full drug-interaction review against the individual patient’s medication list is required before use; if that review, or a pregnancy or lactation check, is positive, do not initiate a prokinetic without specialist involvement.
A watch-and-escalate ladder. In this article, “severe” has a concrete operational meaning: unintentional weight loss over weeks, an inability to hold down food or fluids, or reliance on liquids alone to keep weight stable — and in ME/CFS terms this often coincides with being bed-bound or largely unable to manage oral intake. These are our working thresholds, not published triage criteria. A patient already living on liquids and still losing weight is not approaching the escalation point; they are already at the point where a review of non-oral feeding belongs on the table. These are the signals that move a case up the ladder, from the dietary measures above to liquid or semi-liquid nutrition and then, if weight and nutrition keep falling despite that, to non-oral feeding under medical supervision. These are thresholds a clinician should watch and respond to — not lines the patient is expected to draw alone. Three cautions follow. First, escalation past diet — non-oral feeding, and in a severe patient starting any prokinetic — is usually a specialist (gastroenterology or nutrition-team) decision. Second, some signals warrant urgent attention rather than a slow step up: weight loss continuing week over week, an inability to keep fluids down for roughly a day, or faintness or dizziness that is new or worse and tied to fluids not staying down, rather than your usual orthostatic symptoms. Third, seek urgent care rather than waiting on any of the above for vomiting blood or suspected aspiration. In practice, laboratory checks for electrolyte and micronutrient balance support the decision at each step.
This is not a recommendation to take any of these drugs. Medication decisions require a qualified clinician who can weigh the individual patient’s severity, comorbidities, and current medication list.
8 How to bring this up with your clinician
If this article matches what you feel, the finding is testable. You can ask your clinician whether a gastric emptying study is worth considering given how thin the ME/CFS evidence is, and mention that you would like the result read against a standard protocol. The study can confirm whether emptying is delayed and rule out a normal stomach, but it does not by itself identify the mechanism — it is one useful test, not the whole answer. And if you are losing weight, eating only liquids, or vomiting regularly, say so plainly: those are the signals that make an emptying study and a nutritional assessment worth doing, not optional extras. It is the clinician’s role to decide whether or how to act on those signals, not yours alone. If an emptying study is not immediately available, the safest first-line steps here — dietary measures and a medication review — are still the right place to start, so you are not blocked by waiting for the test.
9 What to take away
Gastroparesis in ME/CFS is real and testable. Delayed gastric emptying is a documented, measurable feature of the illness — not a vague complaint — and it can be assessed with a standard gastric emptying test (Burnet and Chatterton 2004).
The mechanism is genuinely unresolved. Three candidates are on the table — structural loss of the stomach’s pacemaker cells and enteric nerves (open question, 0.40), autoimmune ganglionic blockade (speculation, 0.30), and functional vagal failure alone — and no test currently separates them in ME/CFS. This uncertainty is honest, and it is not a barrier to care.
There is a safe treatment ladder. Dietary and nutritional management first — small, frequent, low-fat, low-fibre meals and liquid options, with enteral support reserved for feeding failure. Prokinetics second, safety-managed, time-limited, and only after a clinician has weighed the individual risks.
The single most actionable conclusion for a severe case: start with the lowest-risk measures — diet and a medication review — regardless of the scan, and treat the measurable problem objectively rather than assuming a specific lesion until it is demonstrated. The emptying study is the confirmatory test to obtain where available, not a precondition for beginning the safest first-line steps.
This article reflects research with explicit, calibrated certainty — a documented clinical finding (0.60), an open mechanism question (0.40), and a registered speculation (0.30) — not established clinical fact. Discuss any medical decision, including any change to diet or medication, with a qualified clinician.
For the broader GI-dysmotility and SIBO framing, see GI Dysmotility Article 1 and the companion treatment article.
For the comprehensive, fully-cited picture of how gastroparesis is weighed among the many candidate mechanisms in ME/CFS, see (Loth 2026).